AC
PTLA

Ascend Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Ascend Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-207,113
Closed -$7.82M – 234
2018
Q2 		$7.82M Buy
207,113
+42,303
+26% +$1.62M 0.37% 95
2018
Q1 		$5.38M Buy
+164,810
New +$7.23M 0.22% 117

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ascend Capital's PTLA Position: Q3 2018 in Review

Ascend Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 207,113 shares — an estimated $7.82M sold.

Ascend Capital first reported a position in PTLA in Q1 2018 and held it in 2 quarters. The position peaked at $7.82M in Q2 2018. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

  • Ascend Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ascend Capital sold 207,113 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $7.82M.
  • Ascend Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Ascend Capital's Portola Pharmaceuticals, Inc. position peaked at $7.82M in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.